eligibility_summary
Adults (>=18) with measurable antiandrogen-refractory mCRPC, prior 2GAA (enzalutamide/abiraterone), NRG-1 >=4 ng/mL, ECOG 0-2, adequate marrow/renal/hepatic function, LVEF >=50%, consent and provide blood/tissue. Exclude recent MI/CHF, serious/uncontrolled cardiac disease, VTE <=60d, unresolved toxicities/infection, immunocompromised or HIV on ART, other active cancer <=3y, pregnancy, drug hypersensitivity, interacting/investigational meds, or other serious comorbidity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in metastatic castration-resistant prostate cancer (enzalutamide-refractory, enriched for high plasma NRG1) testing Phesgo (pertuzumab + trastuzumab + hyaluronidase-zzxf) SC q21d plus oral enzalutamide. Pertuzumab (anti-HER2 IgG1 mAb) blocks HER2 dimerization—especially HER2/HER3—suppressing downstream PI3K/AKT/MAPK signaling. Trastuzumab (anti-HER2 IgG1 mAb) inhibits HER2 signaling and mediates ADCC. Hyaluronidase-zzxf (endoglycosidase) facilitates/extends SC absorption of the antibodies. Enzalutamide (small-molecule androgen receptor inhibitor) blocks AR binding, nuclear translocation, and transcription. Targets: HER2/HER3 (ERBB2/ERBB3) and AR pathways in prostate cancer cells, NRG1-driven HER3 activation is a key correlative focus.